CY1111913T1 - Συνδυασμος σταθερης δοσης φυτικου αλατος και ψευδαργυρου - Google Patents

Συνδυασμος σταθερης δοσης φυτικου αλατος και ψευδαργυρου

Info

Publication number
CY1111913T1
CY1111913T1 CY20111100955T CY111100955T CY1111913T1 CY 1111913 T1 CY1111913 T1 CY 1111913T1 CY 20111100955 T CY20111100955 T CY 20111100955T CY 111100955 T CY111100955 T CY 111100955T CY 1111913 T1 CY1111913 T1 CY 1111913T1
Authority
CY
Cyprus
Prior art keywords
association
stable dosage
phytate
hydroxyapatite
treatment
Prior art date
Application number
CY20111100955T
Other languages
English (en)
Inventor
Freixedas Félix Grases
Bestard Joan Perelló
Amengual Bernat Isern
Cortés Pilar Sanchís
Almirall Rafael M Prieto
Bauza Antonia Costa
Original Assignee
Universitat De Les Illes Balears
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat De Les Illes Balears filed Critical Universitat De Les Illes Balears
Publication of CY1111913T1 publication Critical patent/CY1111913T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Catalysts (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Dental Preparations (AREA)

Abstract

Η εφεύρεση αναφέρεται σε συνδυασμό σταθερής δόσης 5 φυτικού άλατος και ψευδαργύρου σε συνεργικές αναλογίες για χρήση στη θεραπεία της κρυστάλλωσης του υδροξυαπατίτη. Επωφελώς, ο εν λόγω συνδυασμός είναι υπό γραμμομοριακή αναλογία μεταξύ του φυτικού άλατος και του ψευδαργύρου που υπερβαίνει το 4:1. Η εφεύρεση αφορά επίσης τη χρήση του εν λόγω 10 συνδυασμού για την παραγωγή ενός φαρμάκου για τη θεραπεία, προφύλαξη και/ή πρόληψη της κρυστάλλωσης του υδροξυαπατίτη σε ανθρώπους.
CY20111100955T 2006-02-17 2011-10-06 Συνδυασμος σταθερης δοσης φυτικου αλατος και ψευδαργυρου CY1111913T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200600377A ES2280136B1 (es) 2006-02-17 2006-02-17 Asociacion a dosis fija de fitato y zinc.
EP07726369A EP1984001B1 (en) 2006-02-17 2007-02-14 Fixed-dose association of phytate and zinc

Publications (1)

Publication Number Publication Date
CY1111913T1 true CY1111913T1 (el) 2015-11-04

Family

ID=38007006

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100955T CY1111913T1 (el) 2006-02-17 2011-10-06 Συνδυασμος σταθερης δοσης φυτικου αλατος και ψευδαργυρου

Country Status (18)

Country Link
US (2) US8377908B2 (el)
EP (1) EP1984001B1 (el)
JP (2) JP5554499B2 (el)
CN (1) CN101384266B (el)
AT (1) ATE516035T1 (el)
AU (1) AU2007216453B2 (el)
BR (1) BRPI0707008A2 (el)
CA (1) CA2641216C (el)
CY (1) CY1111913T1 (el)
DK (1) DK1984001T3 (el)
ES (1) ES2280136B1 (el)
MX (1) MX2008010502A (el)
NO (1) NO341286B1 (el)
PL (1) PL1984001T3 (el)
PT (1) PT1984001E (el)
RU (1) RU2415673C2 (el)
SI (1) SI1984001T1 (el)
WO (1) WO2007093611A1 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2280136B1 (es) * 2006-02-17 2008-08-16 Universitat De Les Illes Balears Asociacion a dosis fija de fitato y zinc.
WO2013007018A1 (en) * 2011-07-12 2013-01-17 The Procter & Gamble Company Oral care compositions comprising phytic acid
ES2486441B1 (es) * 2014-04-02 2015-06-11 Universitat De Les Illes Balears Preparaciones combinadas de acidificantes urinarios e inhibidores de la cristalización y su aplicación para el tratamiento o prevención de la litiasis renal fosfática o inducida por fosfato cálcico
MX2017008139A (es) * 2014-12-26 2017-09-18 Colgate Palmolive Co Complejo de zinc y fosfato para el cuidado bucal.
DE102016013737A1 (de) 2016-11-17 2018-05-17 WindplusSonne GmbH Hexahydroxycyclohexanhexaphosphorsäureestersalze zur Behandlung von Kalzinose sowie diätische Lebensmittel mit Hexahydroxycyclohexanhexaphosphorsäureestersalzen als Zusatzstoffe
CN108444985B (zh) * 2018-04-25 2021-02-02 山西省食品药品检验所(山西省药品包装材料监测中心) 一种肾精子icp-ms鉴别方法及应用
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3934001A (en) * 1965-12-07 1976-01-20 Lever Brothers Company Oral compositions containing germicidally active plastic powders
NL149701C (nl) 1965-12-08 1981-05-15 Procter & Gamble Werkwijze voor het bereiden van een tegen tandsteen werkzaam tandverzorgingsmiddel, dat als werkzaam bestanddeel een fosfonzuurderivaat bevat, alsmede gevormd tandverzorgingsmiddel.
US3934002A (en) 1972-06-30 1976-01-20 The Procter & Gamble Company Oral compositions for plaque, caries and calculus retardation with reduced staining tendencies
US4215105A (en) 1978-10-27 1980-07-29 Colgate-Palmolive Company Anticalculus oral composition
JPS5846483B2 (ja) 1979-09-20 1983-10-17 ライオン株式会社 口腔用組成物
JPS5835965B2 (ja) * 1979-07-31 1983-08-05 ライオン株式会社 口腔用組成物
JPS6043322B2 (ja) * 1979-09-05 1985-09-27 ライオン株式会社 口腔用組成物
US4515772A (en) * 1982-06-22 1985-05-07 The Procter & Gamble Company Oral compositions
US4808409A (en) 1984-08-16 1989-02-28 Board Of Trustees, University Of Illinois Low cariogenic sweetening agents
JPS6229526A (ja) * 1985-08-01 1987-02-07 Wakamoto Pharmaceut Co Ltd 高カルシウム尿症の治療及び予防剤
US4627977A (en) 1985-09-13 1986-12-09 Colgate-Palmolive Company Anticalculus oral composition
US4808401A (en) * 1985-09-13 1989-02-28 Colgate-Palmolive Company Anticalculus oral composition
JPH0729909B2 (ja) * 1986-11-28 1995-04-05 ライオン株式会社 口腔用組成物
JPH01305033A (ja) * 1988-06-01 1989-12-08 Sanwa Kagaku Kenkyusho Co Ltd 循環改善剤及び循環改善機能性食品並びにし好品
ES2007238A6 (es) * 1988-06-17 1989-06-01 Univ Illes Balears Procedimiento para la preparacion de fitato-zn (ii)>
US5286479A (en) * 1991-12-10 1994-02-15 The Dow Chemical Company Oral compositions for suppressing mouth odors
US5300289A (en) 1991-12-10 1994-04-05 The Dow Chemical Company Phytate antimicrobial compositions in oral care products
CN1102978A (zh) * 1993-11-23 1995-05-31 姚焕新 多功能牙膏
JPH08104635A (ja) * 1994-10-06 1996-04-23 Ichimaru Pharcos Co Ltd フィチン酸亜鉛を有効成分とする外用製剤
JPH10182383A (ja) * 1996-12-24 1998-07-07 Lion Corp 口腔用組成物
IT1306133B1 (it) * 1999-04-22 2001-05-30 Sigma Tau Healthscience Spa Composizione comprendente una carnitina ed un inositolfosfato, utilequale integratore dietetico o medicamento.
JP2004065249A (ja) * 2002-06-13 2004-03-04 Fumio Hara フィチン酸、イノシトールおよびナイアシンの富化方法、食品の製造方法、並びに食品
ES2232302B1 (es) * 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
CN1259033C (zh) 2004-06-24 2006-06-14 江西航天日用化工发展有限责任公司 可去除烟黄斑牙垢的复方牙膏及其制备方法
JP2009519235A (ja) * 2005-11-29 2009-05-14 ザ プロクター アンド ギャンブル カンパニー 親水性粘土材を含む結合剤系を備える歯磨剤組成物
WO2007076001A2 (en) * 2005-12-20 2007-07-05 The Procter & Gamble Company Oral care compositions comprising zinc and phytate
ES2280136B1 (es) * 2006-02-17 2008-08-16 Universitat De Les Illes Balears Asociacion a dosis fija de fitato y zinc.

Also Published As

Publication number Publication date
ES2280136B1 (es) 2008-08-16
US20140056994A1 (en) 2014-02-27
JP2009526818A (ja) 2009-07-23
CA2641216C (en) 2014-04-15
AU2007216453B2 (en) 2012-09-27
JP5554499B2 (ja) 2014-07-23
NO20083901L (no) 2008-09-11
DK1984001T3 (da) 2011-11-07
BRPI0707008A2 (pt) 2011-04-12
EP1984001B1 (en) 2011-07-13
PL1984001T3 (pl) 2012-02-29
NO341286B1 (no) 2017-10-02
ATE516035T1 (de) 2011-07-15
CA2641216A1 (en) 2007-08-23
PT1984001E (pt) 2011-10-18
CN101384266B (zh) 2013-03-20
JP2014139182A (ja) 2014-07-31
EP1984001A1 (en) 2008-10-29
RU2415673C2 (ru) 2011-04-10
ES2280136A1 (es) 2007-09-01
MX2008010502A (es) 2008-10-23
US20090035232A1 (en) 2009-02-05
RU2008138358A (ru) 2010-03-27
WO2007093611A1 (en) 2007-08-23
JP5908933B2 (ja) 2016-04-26
SI1984001T1 (sl) 2011-12-30
US8377908B2 (en) 2013-02-19
AU2007216453A1 (en) 2007-08-23
CN101384266A (zh) 2009-03-11
US9144578B2 (en) 2015-09-29

Similar Documents

Publication Publication Date Title
CY1111913T1 (el) Συνδυασμος σταθερης δοσης φυτικου αλατος και ψευδαργυρου
MY157944A (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associat ed with angiogenesis
ATE551063T1 (de) Verwendung von bifidobacterium longum zur prophylaxe und behandlung von entzündungen
MX2009005308A (es) Composiciones que comprenden peroxido de benzoilo, al menos un derivado del acido naftoico y al menos un compuesto del tipo polimeros de poliuretano o derivados de estos y sus usos.
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
MX2007000224A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de nauseas y vomitos.
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
EA200701820A1 (ru) Применение диосметиновых соединений при лечении и профилактике тромботических патологий
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
TW200806300A (en) New therapeutic combinations for the treatment of depression
TW200734334A (en) Treatment of substance abuse
RS51790B (en) USE OF BENZO-CONDENSED HETEROCYCLIC SULFAMIDES DERIVATIVES FOR MANIA AND BIPOLAR DISORDER TREATMENT
SG178975A1 (en) Indenone derivative and pharmaceutical composition comprising same
ATE457729T1 (de) Verwendung von allopurinol zur behandlung von palmarer/plantarer erythrodysästhesie
TW200724146A (en) Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
BRPI0509667A (pt) azaquinazolinas substituìdas com eficácia antiviral
BRPI0911678B8 (pt) maleato de orvepitant cristalino anidro, composição farmacêutica compreedendo o dito maleato e uso do mesmo para o tratamento ou profilaxia de doenças do sistema nervoso central
EP2801359A3 (en) The use of nicotine for the treatment of sepsis in humans caused by antibiotic
DE502006001740D1 (de) Zusammensetzung zur Vorbeugung und Behandlung von Erkältungskrankheiten
CL2008002223A1 (es) Compuestos derivados de 9-desoxo-9a-metil-9a-aza-9a-homoeritromicina a 2'-o-sustituida; proceso de preparación; compuesto intermediario; composición farmacéutica; y su uso en el tratamiento y/o profilaxis de la malaria.
EA200802262A1 (ru) Назальные и буккальные композиции для борьбы с храпом
WO2007138233A3 (fr) Utilisation du zatosetron pour le traitement de la rosacee
WO2006026172A3 (en) Use of soluble cd26 as inhibitor of angiogenesis and inflammation
MXPA01009032A (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso se la produccion de il-12.
DE602006009511D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Hauterkrankungen